Showing results (1-10 of 207) with videos related to
Sort By:
Pageof 21
Current Treatment Options in Oncology|July 6, 2004
Bcl-2 antisense therapy in B-cell malignant proliferative disordersAsher Chanan-Khan, Myron S CzuczmanCurrent Opinion in Oncology|August 23, 2002
Radioimmunotherapy in non-Hodgkin lymphomaAsher Chanan-Khan, Myron S CzuczmanThe Journal of Supportive Oncology|August 27, 2004
Prevention and management of cardiotoxicity from antineoplastic therapyAsher Chanan-Khan, Sridhar Srinivasan, Myron S CzuczmanBritish Journal of Haematology|November 30, 2004
Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximabJeyanthi Ramanarayanan, Francisco J Hernandez-Ilizaliturri, Asher Chanan-Khan, et al.HIV Clinical Trials|July 13, 2004
Clinical characteristics of gastrointestinal lymphomas associated with AIDS (GI-ARL) and the impact of HAARTSridhar Srinivasan, Kenichi Takeshita, Beata Holkova, et al.Current Opinion in Oncology|January 1, 2005
Bcl-2 antisense therapy in hematologic malignanciesAsher Chanan-KhanLeukemia & Lymphoma|September 17, 2004
Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphomaAsher Chanan-Khan, Tariq Islam, Arif Alam, et al.Hematology. American Society of Hematology. Education Program|November 25, 2006
Controversies in follicular lymphoma: "who, what, when, where, and why?" (not necessarily in that order!)Myron S CzuczmanSeminars in Oncology|June 1, 2002
Immunochemotherapy in indolent non-Hodgkin's lymphomaMyron S CzuczmanPageof 21